190730-49-5

Upstream product

• 190730-43-9 8-methyl-7-nitro-4-oxo-4H-chromene-2-carboxylic acid ethyl ester 
• 66-71-7 1,10-Phenanthroline 
• 190730-47-3 (2S)-[2-(tert-butyl-dimethyl-silanyloxymethyl)-8-methyl-chroman-7-yl]-carbamic acid tert-butyl ester 
• 190730-45-1 7-tert-butyloxycarbonylamino-8-methyl-chroman-2-carboxylic acid ethyl ester 
• 190730-46-2 (RS)-(7-tert-butoxycarbonylamino-8-methyl-chroman-2-yl)-methanol 
• 190730-44-0 7-amino-8-methyl-chroman-2-carboxylic acid ethyl ester 
• 190730-40-6 1-(2-hydroxy-3-methyl-4-nitrophenyl)ethanone 
• 5460-31-1 3-nitro-o-cresol 
• 98-59-9 p-toluenesulfonyl chloride 
• 190730-48-4 2-(3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indol-8-one)-methanol 

Relevant academic research and scientific papers

New generation dopaminergic agents 4. Exploiting the 2-methyl chroman scaffold. Synthesis and evaluation of two novel series of 2-(aminomethyl)- 3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and indol-8-one derivatives

The rational design, synthesis, and evaluation of two novel series of 2- (aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and indolone derivatives are disclosed, based on the recently discovered D2 agonist phenolic template prototype [i.e. the 7-OH-2-(aminomethyl)chroman nucleus]. The indolones were observed to have higher affinity and intrinsic activity than the corresponding indoles.